Michael J. Kamdar is the CEO and board member of Molecular Assemblies, a privately held company focused on the next-generation of DNA synthesis. Prior to this, he was president and board member at Ciclofilin Pharmaceuticals, a company focused on development of novel Hepatitis B (HBV) compounds, which was sold to ContraVir Pharmaceuticals in June 2016. Kamdar was previously president and board nember of Cellana, a leading developer of algae-based products, and the founder, chief business officer, and director at Genoa Pharmaceuticals, a company developing a treatment for idiopathic pulmonary fibrosis. He also founded VentiRx Pharmaceuticals, which was optioned to Celgene Corporation in 2012.
Over the past 20-plus years, Kamdar has accounted for deal transactions in excess of $1 billion and has raised more than $400M from venture capital and the public capital markets. Prior to VentiRx, Kamdar held several positions at Anadys Pharmaceuticals, and played an instrumental role in the company’s successful IPO. He also held several senior management positions at Agouron Pharmaceuticals, including business development positions and responsibilities that culminated with his assumption of global responsibility for corporate partnering, in-licensing, technology acquisition, and strategic alliance efforts in the anti-infective, oncology, and ophthalmology therapeutic areas. Before that, Kamdar held various product management and new product planning positions for Hybritech under Eli Lilly and Centocor, Inc.
Kamdar is a board chairman at Medipacs, and a board member at Prime Genomics and Vault Pharma. He previously served on the board of Tobira Therapeutics. He received his B.S. in Biology from St. Joseph's University and his M.B.A. from Villanova University.